| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2530694 | Current Opinion in Pharmacology | 2006 | 6 Pages |
Abstract
Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erthyroid precursors. Advances in our understanding of the novel sites of action of EPO in the vasculature, brain, heart and kidney have opened new avenues of therapeutic potential for EPO, and have led to an increased understanding of the biological roles of EPO and its mechanisms of cell protection.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Edward J Sharples, Christoph Thiemermann, Magdi M Yaqoob,